Walder Wyss advised TECregen, as the Basel-based biotechnology company raised CHF 10 million in a seed financing round. The investor base Boehringer Ingelheim Venture Fund (BIVF) led the round in question, with participation from LifeSpan
Walder Wyss advised TECregen, as the Basel-based biotechnology company raised CHF 10 million in a seed financing round. The investor base Boehringer Ingelheim Venture Fund (BIVF) led the round in question, with participation from LifeSpan